To investigate this at a cellular level, we exposed non-dysplastic BE (BAR-T and CP-A), high-grade dysplastic BE (CP-B and CP-D) and EAC (FLO-1 and OE-33) cell lines to the same sublytic dose of immunopurified human C9 (3 μg/ml) in the presence of C9-depleted human serum. The gene discussed is C9; the disease is Barrett esophagus.